drug

Reboxetine

MeSH D000077593
as of 2026-07-01
Add to landscapeMonitor thisCompare thisAsk about this
at a glance
small molecule
Pre-approval / investigational in the US
Developed by Fundació Sant Joan de Déu
2 trials in the graph
Synthesized from structured facts only — each point cited above.

Mechanism & identity

Modality
small molecule

Indications

Trials

2
Pharmacovigilance in Gerontopsychiatric Patients
NCT02374567Phase 3Terminated
Reboxetine and Citalopram as an Adjunct Treatment to Second Generation Antipsychotics in the Treatment of Negative Symptoms of Schizophrenia
NCT01300364Phase 4Unknown

KOLs & investigators

1
Helge Frieling, Prof., MDKOL score 5

Facts & assertions

0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
Fundació Sant Joan de Déu
company
trial
Pharmacovigilance in Gerontopsychiatric Patients
PHASE3
trial
Reboxetine and Citalopram as an Adjunct Treatment to Second Generation Antipsychotics in the Treatment of Negative Symptoms of Schizophrenia
PHASE4
trial
indication
Schizophrenia
indication
Depression
indication
Psychosomatic Disorders
indication
Schizophrenia
indication
KOL
Helge Frieling, Prof., MD
KOL score 5
person